|
1
|
Jia G, Whaley-Connell A and Sowers JR:
Diabetic cardiomyopathy: A hyperglycaemia-and
insulin-resistance-induced heart disease. Diabetologia. 61:21–28.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aneja A, Tang WH, Bansilal S, Garcia MJ
and Farkouh ME: Diabetic cardiomyopathy: Insights into
pathogenesis, diagnostic challenges, and therapeutic options. Am J
Med. 121:748–757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y,
Tan Y, Cui W, Liu B, Cui T, et al: Therapeutic effect of MG-132 on
diabetic cardiomyopathy is associated with its suppression of
proteasomal activities: Roles of Nrf2 and NF-κB. Am J Physiol Heart
Circ Physiol. 304:H567–H578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guan SJ, Ma ZH, Wu YL, Zhang JP, Liang F,
Weiss JW, Guo QY, Wang JY, Ji ES and Chu L: Long-term
administration of fasudil improves cardiomyopathy in
streptozotocin-induced diabetic rats. Food Chem Toxicol.
50:1874–1882. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scheen AJ: Cardiovascular effects of new
oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ
Res. 122:1439–1459. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drucker DJ: The biology of incretin
hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Drucker DJ, Habener JF and Holst JJ:
Discovery, characterization, and clinical development of the
glucagon-like peptides. J Clin Invest. 127:4217–4227. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Drucker DJ: The cardiovascular biology of
glucagon-like peptide-1. Cell Metab. 24:15–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM,
Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M and Drucker
DJ: GLP-1R agonist liraglutide activates cytoprotective pathways
and improves outcomes after experimental myocardial infarction in
mice. Diabetes. 58:975–983. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dokken BB, La Bonte LR, Davis-Gorman G,
Teachey MK, Seaver N and McDonagh PF: Glucagon-like peptide-1
(GLP-1), immediately prior to reperfusion, decreases neutrophil
activation and reduces myocardial infarct size in rodents. Horm
Metab Res. 43:300–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marso SP, Daniels GH, Brown-Frandsen K,
Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR,
Ravn LS, et al: Liraglutide and cardiovascular outcomes in type 2
diabetes. N Engl J Med. 375:311–322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marso SP, Bain SC, Consoli A, Eliaschewitz
FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren
ML, et al: Semaglutide and cardiovascular outcomes in patients with
type 2 diabetes. N Engl J Med. 375:1834–1844. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nauck MA, Meier JJ, Cavender MA, Abd El
Aziz M and Drucker DJ: Cardiovascular actions and clinical outcomes
with glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors. Circulation. 136:849–870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rizzo M, Abate N, Chandalia M, Rizvi AA,
Giglio RV, Nikolic D, Marino Gammazza A, Barbagallo I, Isenovic ER,
Banach M, et al: Liraglutide reduces oxidative stress and restores
heme oxygenase-1 and ghrelin levels in patients with type 2
diabetes: A prospective pilot study. J Clin Endocrinol Metab.
100:603–606. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rizzo M, Rizvi AA, Patti AM, Nikolic D,
Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G,
Provenzano V, et al: Liraglutide improves metabolic parameters and
carotid intima-media thickness in diabetic patients with the
metabolic syndrome: An 18-month prospective study. Cardiovasc
Diabetol. 15:1622016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Liu Y, Chen L, Wang Y and Li J:
Glucagon-like peptide-1 analog liraglutide protects against
diabetic cardiomyopathy by the inhibition of the endoplasmic
reticulum stress pathway. J Diabetes Res. 2013:6305372013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inoue T, Inoguchi T, Sonoda N, Hendarto H,
Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D and
Takayanagi R: GLP-1 analog liraglutide protects against cardiac
steatosis, oxidative stress and apoptosis in streptozotocin-induced
diabetic rats. Atherosclerosis. 240:250–259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noyan-Ashraf MH, Shikatani EA, Schuiki I,
Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker
DJ and Husain M: A glucagon-like peptide-1 analog reverses the
molecular pathology and cardiac dysfunction of a mouse model of
obesity. Circulation. 127:74–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Xue R, Wu D, Wu L, Chen C, Tan W,
Chen Y and Dong Y: REDD1 attenuates cardiac hypertrophy via
enhancing autophagy. Biochem Biophys Res Commun. 454:215–220. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arturi F, Succurro E, Miceli S, Cloro C,
Ruffo M, Maio R, Perticone M, Sesti G and Perticone F: Liraglutide
improves cardiac function in patients with type 2 diabetes and
chronic heart failure. Endocrin. 57:464–473. 2017. View Article : Google Scholar
|
|
21
|
Okada K, Kotani K, Yaqyu H, Ando A, Osuqa
J and Ishibashi S: Effects of treatment with liraglutide on
oxidative strss and cardiac natriuretic peptide levels in patients
with type 2 diabetes mellitus. Endocrine. 47:962–964. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dai Y, Mehta JL and Chen M: Glucagon-like
peptide-1 receptor agonist liraglutide inhibits endothelin-1 in
endothelial cell by repressing nuclear factor-kappa B activation.
Cardiovasc Drugs Ther. 27:371–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nandy D, Johnson C, Basu R, Joyner M,
Brett J, Svendsen CB and Basu A: The effect of liraglutide on
endothelial function in patients with type 2 diabetes. Diab Vasc
Dis Res. 11:419–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo S, Yao Q, Ke Z, Chen H, Wu J and Liu
C: Resveratrol attenuates high glucose-induced oxidative stress and
cardiomyocyte apoptosis through AMPK. Mol Cell Endocrinol.
412:85–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang F, Lin X, Yu L, Li W, Qian D, Cheng
P, He L, Yang H and Zhang C: Low-dose radiation prevents type 1
diabetes-induced cardiomyopathy via activation of AKT mediated
anti-apoptotic and anti-oxidant effects. J Cell Mol Med.
20:1352–1366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Despa S, Margulies KB, Chen L, Knowlton
AA, Havel PJ, Taegtmeyer H, Bers DM and Despa F: Hyperamylinemia
contributes to cardiac dysfunction in obesity and diabetes: A study
in humans and rats. Circ Res. 110:598–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Monji A, Mitsui T, Bando YK, Aoyama M,
Shigeta T and Murohara T: Glucagon-like peptide-1 receptor
activation reverses cardiac remodeling via normalizing cardiac
steatosis and oxidative stress in type 2 diabetes. Am J Physiol
Heart Circ Physiol. 305:H295–H304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Luo P, Wang Y, Li W, Wang C, Sun
D, Zhang R, Su T, Ma X, Zeng C, et al: Glucagon-like peptide-1
protects against cardiac microvascular injury in diabetes via a
cAMP/PKA/Rho-dependent mechanism. Diabetes. 62:1697–1708. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
XiaoTian L, QiNan W, XiaGuang G, WuQuan D,
Bing C and ZiWen L: Exenatide activates the APPL1-AMPK-PPARα axis
to prevent diabetic cardiomyocyte apoptosis. J Diabetes Res.
2016:42197352016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim M, Platt MJ, Shibasaki T, Quaggin SE,
Backx PH, Seino S, Simpson JA and Drucker DJ: GLP-1 receptor
activation and Epac2 link atrial natriuretic peptide secretion to
control of blood pressure. Nat Med. 19:567–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Richards P, Parker HE, Adriaenssens AE,
Hodgson JM, Cork SC, Trapp S, Gribble FM and Reimann F:
Identification and characterisation of glucagon-like peptide-1
receptor expressing cells using a new transgenic mouse model.
Diabetes. 63:1224–1233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ussher JR, Baggio LL, Campbell JE,
Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA,
Seeley RJ and Drucker DJ: Inactivation of the cardiomyocyte
glucagon-like peptide-1 receptor (GLP-1R) unmasks
cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol
Metab. 3:507–517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS,
Drucker DJ and Husain M: Cardioprotective and vasodilatory actions
of glucagon-like peptide 1 receptor are mediated through both
glucagon-like peptide 1 receptor-dependent and -independent
pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Younce CW, Burmeister MA and Ayala JE:
Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis
via inhibition of endoplasmic reticulum stress and activation of
SERCA2a. Am J Physiol Cell Physiol. 304:C508–C518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu H, Chen X, Han Y, Li C, Chen P, Su S,
Zhang Y and Pan Z: Rho kinase inhibition by fasudil suppresses
lipopolysaccharide-induced apoptosis of rat pulmonary microvascular
endothelial cells via JNK and p38 MAPK pathway. Biomed
Pharmacother. 68:267–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao H, Hou F, Dong R, Wang Z, Zhao C, Tang
W and Wu Y: Rho-Kinase inhibitor fasudil suppresses high
glucose-induced H9c2 cell apoptosis through activation of
autophagy. Cardiovasc Ther. 34:352–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
